LDK-378|LDK-378 is an anaplastic lymphoma kinase (ALK) inhibitor that displays anticancer chemotherapeutic activity. LDK-378 is currently in clinical trials as a potential treatment for non-small-cell lung cancer (NSCLC). This compound also inhibits IGF-1R.|C28H36ClN5O3S|558.13|off-white powder|-20°C|In DMSO